
Mark L. Lewis, Executive Chairman, has participated in the life sciences industry for over 45 years developing and commercializing platforms and technologies for DNA sequencing, genotyping, flow cytometry, molecular biology, PCR, high content screening and confocal imaging. He has held research and development, commercial, and general management roles at leading organizations including Illumina, BD Biosciences, Swift Biosciences, Molecular Dynamics, Nycomed-Amersham, and Beckman Instruments. Currently, Mark is Executive Chairman for Miroculus, a digital microfluidic company focused on automated sample preparation systems for sequencing and other life science applications. Mark is also a board member at AEENA (formerly Prime Genomics), developing cancer detection, diagnosis and management systems and an advisor for S2 Genomics, a single cell and nuclei isolation company. In his most recent full-time role, Mark served in an interim CEO role at Swift Biosciences in 2017 & 2018 and as a board member until Swift’s acquisition by Danaher early in 2021. Previously, Mark held Senior Vice President roles at Illumina, a leading supplier of systems for genetic analysis, in Product Development, General Management, and Customer Support. Mark directed the development of the HiSeqTM and MiSeq TM next-generation sequencing platforms and supporting reagents. Mark is a member of the Dean’s Leadership Council for Biological Sciences at University of California at San Diego. Mark has served as a volunteer co-instructor for Professional Pathways Courses for life science graduate students and post-docs at UCSD. Mark earned a Bachelor of Arts in Biology from UC San Diego.